Nystagmus Market Research Report鈥揊orecast till 2032

Nystagmus Market Share And Application By Type (Infantile, Latent Nystagmus, Noonan Syndrome, Nystagmus Blockage Syndrome) Diagnosis (Ct Scan, Mr Scan, Chromosome Analysis, Ultrasonography) Treatment (Medication, Surgical) End-User-Forecast Till 2032

ID: MRFR/Pharma/3995-HCR | 110 Pages | Author: Rahul Gotadki | March 2024         

Nystagmus Market Speak to Analyst Request a Free Sample

Nystagmus Market Overview


The Nystagmus Market is expected to reach USD 3.3 Billion by 2032 at 7.7% CAGR during the forecast period 2023-2032. Nystagmus is a vision-related medical disease characterized by uncontrolled and repeated eye movements. These motions frequently result in blurred vision, which may wreak havoc on the body's balance and coordination. The prognosis of nystagmus is worsened by fatigue and stress. The specific source of the disease, however, is yet unknown. Congenital neurological problems or neurological abnormalities developing in childhood are the most common causes of nystagmus.


Nystagmus can also be caused by a lack of normal eye movement in childhood, refractive errors such as near-sightedness (myopia) or astigmatism, inflammation of the inner ear, medicines such as anti-epilepsy treatments, and central nervous system illnesses. The rising frequency of genetic and eye-related illnesses is driving the expansion of the nystagmus industry. Furthermore, the market will grow as mental retardation and neurological disorders become more prevalent.


Global Nystagmus Market, by region 2016(%)


 global nystagmus


Segmentation:


The nystagmus market is segmented on the basis of type, diagnosis, treatment, and end-users.


Based on the type, the market is segmented into infantile, latent nystagmus, noonan syndrome, and nystagmus blockage syndrome.


On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.


On the basis of the treatment, the market is segmented into medications, surgical, and others.


On the basis of the end-user, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.


Regional Analysis:


The global nystagmus market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominate the global nystagmus market owing to well-developed technology, increasing number of patients with LASIK eye-related problems, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies in the region have fuelled the growth of the market in this region.  


Europe holds the second position in the global nystagmus market owing to the government support for research & development and availability of funds for research. Moreover, this is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing their investments in the healthcare domain.     


Asia Pacific is the fastest growing nystagmus market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods for eye diseases in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, growing demand for quality devices in the healthcare sector is projected to lead the use of advanced equipment, which, in turn, will increase the market growth of nystagmus in the region.  


On the other hand, in the Middle East and Africa, eye problems have become a huge issue due to limited screening, ignorance of diseases, and poor access to treatment.


Key Players:


Some of key the players in the global nystagmus market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.Recent Development


Regeneron Pharmaceuticals, Inc. is a biotechnology business that specializes in drug research, development, manufacturing, and commercialization. EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP are among the company's product lines. The company's own VelociSuite technologies, such as VelocImmune, which employs genetically humanized mice to manufacture optimized totally human and bispecific antibodies, help to speed up the traditional drug development process.


Bristol-Myers Squibb is a biopharmaceutical corporation. Biopharmaceutical products are discovered, developed, licensed, manufactured, marketed, distributed, and sold by the company. Oncology, immunology, cardiovascular disease, and fibrosis are among the therapeutic classes for which the company produces pharmaceuticals. Chemically manufactured or tiny molecule medications, as well as biologics created through biological processes, are among the company's pharmaceutical goods. Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude, and Breyanzi are some of the company's products. Wholesalers, distributors, pharmacies, merchants, hospitals, clinics, and government organizations are all customers of its goods.


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Research Methodology:


  nystagmus


Sources: Annual reports, Press release, White paper, and Company presentation

Report Scope:

Report Attribute/Metric Details
聽聽Market Size 聽聽USD 3.4 Billion
聽聽CAGR 聽聽7.7%
聽聽Base Year 聽聽2021
聽聽Forecast Period 聽聽2023-2032
聽聽Historical Data 聽聽2020
聽聽Forecast Units 聽聽Value (USD Million)
聽聽Report Coverage 聽聽Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
聽聽Segments Covered 聽聽Type, diagnosis, treatment, and end-users
聽聽Geographies Covered 聽聽North America, Europe, Asia-Pacific, and Rest of the World (RoW)
聽聽Key Vendors 聽聽Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others
聽聽Key Market Opportunities 路聽 Increasing number of patients with eye-related problems 路聽 High healthcare spending 路聽 Increasing government support for research & development
聽聽Key Market Drivers 路聽 Increasing prevalence of the genetic and eye related disorders 路聽 Increasing mental retardation and neurological abnormalities




Frequently Asked Questions (FAQ) :

Nystagmus market is expected to exhibit a CAGR of 7.7% from 2022-2032.

Nystagmus market is driven by the high prevalence of genetic and eye disorders.

Lack of effective reimbursement schemes and offering of expensive treatment can hamper the global nystagmus market growth.

The Americas can be dominant in the global nystagmus market till 2030.

Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bayer AG, NUSAPURE, ALLERGAN, Novartis AG, Genentech, Inc., Aerie Pharmaceuticals, Inc., Pfizer Inc., Shire, Bristol-Myers Squibb Company, and Valeant Pharmaceuticals International, Inc. are key players of the global nystagmus market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players鈥 financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid